{
    "nctId": "NCT04993430",
    "briefTitle": "A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer",
    "officialTitle": "A Phase 1, Single Arm, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "ER-Positive, HER2-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "MTD",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histological diagnosis of metastatic or locally advanced breast cancer; Histologically proven diagnosis of ER-positive, HER2-negative;\n2. At least 1 line of endocrine therapy in the metastatic or advanced setting that had progressed or intolerance; \u2264 2 lines of chemotherapy for metastatic or advanced disease;\n3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1;\n4. Expected survival of more than 3 months.\n\nExclusion Criteria:\n\n1. All patients in monotherapy and or in combination wih phase who are known allergic to HRS8807 or SHR6390 ingredient;\n2. Presence of symptomatic metastatic visceral disease ;\n3. Patients with known active brain metastases;\n4. Clinically serious cardiovascular disease;\n5. Abnormal electrocardiographic (ECG) with clinical significancy by investigator judgement;\n6. Abnormal thyroid function laboratory results;\n7. Active infection or unexplained fever \\>38.5\u2103 during screening period or on the day of the first dose.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}